Artelo Biosciences (ARTL)
(Delayed Data from NSDQ)
$1.08 USD
-0.01 (-0.92%)
Updated Sep 26, 2024 03:57 PM ET
After-Market: $1.09 +0.01 (0.93%) 5:18 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
Artelo Biosciences, Inc. [ARTL]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Gaining Momentum Going Into 2H24; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ART26.12 Progress Supported by New Preclinical Results in Pain Management
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results: On Track to Start CAReS Phase 2a Enrollment in 2024; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results: CAReS Progresses to Efficacy Evaluation Stage; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results: Great Care in Making Pipeline Progress; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our KOL Webinar on Cancer Cachexia; Reiterate Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ART27.13 Advances to Phase 2a Study; Reiterate Buy With PT Adjusted to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Final Cohort in ART27.13 CAReS Phase 1b Trial Enrollment Completed; Reiterate Buy Rating and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CAReS Phase 2a on Track to Commence Near YE22; Reiterate Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Promising Early Data Suggests FABP5 Program Expansion Into Anxiety-Related Disorders; Reiterate Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CAReS Phase 1b Completion on Track for 4Q22; Reiterate Buy With Reverse Split-Adjusted PT of $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment of First Three Cohorts in CAReS Study Completed; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CAReS Very Much Strongly Positioned; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results Show Promise For CARes Trial Readout Later This Month; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Looking for CARes Phase 1b Data This Month to be Positive; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Expecting Positive CAReS ART27.13 Phase 1 Results; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Year 2021 Results; CARes Phase 1b Readout Expected in 1Q22; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
A Pipeline that CAReS About Anorexia and Other Unmet Needs in Cancer; Initiate at Buy and $4.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Artelo Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
|